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toreandplaya role in heattfailure,coronaryheartdisease,andpulmonary
hypertension(PHT). In vitro studiesshowedthat ET I is releasedfrom
culturedendothelialcellsduringhypoxemia.Obstruefivesleepapnoeasyn-
drome(OSAS)is associatedwith hypoxemiathat altersthe cardiovascular
system.Aimof ourstudywasto provewhetherhypoxemiain manstimulates
releaseof ET L Methods.’In 10 malepatients(pts.;meanage 57.9 + 5.5
y), we meSSUred the circulatingET l-, AT H-,Norepinephrine-(NEPI), and






significantlyafterTher.I and II parallelto a significantdecreaseof RDIand
ODI.NEPIandEPIshowednosignificantchanges.
Rest Diaa. Ther. I Thor. II
RDI n/h 6t.09+21.77 25.93+ 19.t4# 8.33& 8.44~
ODI nfh 57.56 + 23.2S 19.85 + 18.01# 5,19 * 3.635
ET I {pmolfl) 0.98 +0.9S 0673+ 7.16’ 0.88 & 0.76# 0.49+ 0.65$
AT II {nmoljl) 12.48 + 1.49 15.40 + 2.61* 12.98* 1.99# 12.03+ 1.409
values are mesns + SD; “p <0.05 Rest vs Diag.;#p <0.05 Ther. I vs Diag.; 5p <0.05
Ther. II vs Diag.
Conclusion:1. Releaseof ETI istriggeredbyhypoxemiaandATH-levels
areelevatedinpts.withOSAS.2.AdequatetreatmentwithCPAPresultsina







Dueto a variableinfluenceof closingpressureonpulmonatyvascularresis-
tance,the responseof pulmonaryresistancevesselsto variousvasodilators
is bestmeasuredunderstabledrivingpressuresand cardiacoutput.This




pressure12* 9 mmHg,pulmonawvascularresistance13+ 8 WoodUnits).
Bioodflow veloeitywas measuredwith a flow wire (0.018”)positioned
in a pulmonaryarterybranchwith a diameterof 3-6 mm as determined
by intravascularultrasound.Drug infusionewereadjustedto providelocal
concentrationsof 10-6-10-4 M Acetylcholine(max.2.5 mglmin),3.12.5-
50.0ng/mi/secProefaglandinEI (max. 8.5 &@kg/min)in the targetvessel,
0.125-1.0@/k@minsodiumnitroprussideand5 mgNifedipintmlus.
Achcauseda significantdose-dependentincreasein bloodflowveioc-
ity withoutmncomitantchangesin pulmonaryor systemichemodynamics
(table).
A flOWVelOCity Responder> 20%) ACardiacoutput
Acarvkholina 12s% i 31%”* 9/10 –0.57 Vmin............
Nlfedipin 56”A+ 1l”A* 5/5 +0.66 Vmin
PGE1 47% * 15% 5/6 +1.12 !Jmin
SNP 31% * 10% 419 +0.50 lrmin











EndothelinplasmaIeveisare elevatedin atherosclerosis,in myocardialin-
farctionand in acutecoronarysyndromes.Toelucidatethe effectsandthe










Resuk All patientshadan impairedCFR(< 2.0, n.s.vs placebo).No
seriousadverseeventswereobservedafterinfusionof bosentan;2 ptshada
transient asymptomatic hypotension, 3 patientshadanginapeetoris(1 in the
bosentan-group,2 in the placebo-group).BosentanreducedsystolicBP (p
<0.05 after30rein),whileFreatiratedid notchange.CDtendedto increase
afterbosentan(+0.1+ 0.1 mm,n.s.vs placebo).Despitethe decreasein
blood pressureand the slight increasein CD, CBFdid not changeafter
bosentan(n.s.vscontrol).IncreasesinCDcorrelatedinverselywithplasma
LDL4evels(# = 0.56,p < 0.01),
ConcbsiorxBoeentanis safein patientswithstablecoronaryarterydis-
easeandinspiteof a BPloweringeffecttendsto increaseCBF.Changesin
CDinverselycorrelatewithLDL-cholesterol.Hence,furthertrialswill deter-











useda I=er Dopplerdevieeto evaluatemeanforearmcspiliarybloodflowat
baseline,duringa2-minutebrschialocclusion(OCCL),andatpeakbloedflow
duringthe pestleehemichyperemicresponse(HYP)in a totaiof 61 healthy
premenopausal(PREMENO)and postmenopausalwomen.Basellneskin
temperatureand bloodpressuredid not differ in postmenopausalwomen
whohadnevertakenERT(NEVER),thoseon ERTin the past (off ERT>
1 month)(PAST),andthosecurrentlytakinglong-termERT(LONG-TERM).
Forearmcepiilatybloodflow (mean + SD)weeas follows:
Capillay BloodFlow (rluxunits)
n Baseline OCCL HYP
PREMENO 21 13,6+ 3.5 4.6 + 1.1 73.4* we
LONG-TERM 18 17.6+ S.6 3.9 + 1.7 80.9+22.2
NEVER 14 12.9* 3,3 4.1 * 2.0 53.6& 17.0”
PAST 6 13.2+ 4.6 4.4 i 1.5 56.4 k 15.4t
‘p< 0.02; tp <0.001 bothvecsuaLONG-TERM HYP;
Thepeakhyperemicresponsein womenon long-termERTdid notdiffer
from premenopausalwomen.There was a significantdifferencein peak
hyperemicresponseinpostmenopausalwomenonlong-termERTcompsrad
tothatinpostmenopausaiwomenwhohadnevertekenERT.Womenonlong-
termERThada greaterpeakresponsethanthosewho hadtakenit in the
past.Thus,continueduseof long-termoralERTisassoeiatadwithincreaead
endothelialreactivityin postmenopausalwomen:endotheiiaireactivityin
postmenopausalwomenon ERTis notdifferentfromthat in premenopeueai












PHPT(mean& SD;age55 + 15,serumcaiciurn3.0* 0.3 mmoi/L,iPTH
225* 160pg/mL,serumphosphate0.77+ 0.21mmoVL)andnoevidenceof
coronaryarterydisease(CAD)aswellas30normoealcemicpatientswithout
evidenceof CAD(Non-CAD;age 50 + 13)werestudied.Afterwithdrawal
of all vseoactivemedicationfor at ieast24 h vasodilationfollowingreaetive
hyperemia ndafterO.8mgnitroglycerinwereaeeessadinthebrachiaiattery
by usinghighresolutionultrasound(7 MHz).Re.suk NMDwas impairedin
PHPTptsmmpsredtotheNon-CADcontrols(11.7+ 4.2%vs.15.9& 8.0°4;
p < 0.05).FMDwasnotsignificantlydifferentinPHPTpatientsandNon-CAD
